MBA/MB Dual-Degree Program

With over $40 billion invested annually in the U.S. for biomedical R&D and world-wide pharmaceutical sales exceeding $300 billion each year, the need for individuals skilled in biotechnology management is urgent. The University of Pennsylvania is proud to offer one of the deepest immersion experiences in the fields of biotechnology and business.

From evaluating patent positions, licensing and strategic partnerships, and emerging trends in this complex industry, no sector of activity is untouched by new discoveries. DNA microarrays, pharmacogenomics, and proteomic methods present new and complex opportunities. The time from discovery to marketplace can be as short as a year or as long as a decade. High-value activities can evolve from a premium discovery tool to a commodity in just a few years. Penn's dual-degree program in management and biotechnology prepares individuals to meet these challenges and opportunities.

While your background may be in biology, engineering, or computer science, this Dual-Degree Program allows you to achieve in-depth training in recombinant DNA technology, Biopharmaceutical/Medical Device, or Bioinformatics with a grounding in management.

The MBA/Biotechnology Program offers specialized courses in Genomics, Drug Discovery and Development, Pharmaceutical Manufacturing, Biomolecular Engineering, Biotechnology Entrepreneurship, as well as a specialized Biotechnology Seminar where you can meet experts from VC, finance, biotech start-ups, and pharmaceutical houses.

The program's location in Philadelphia gives students easy access to Philadelphia's many biotechnology resources and to its varied cultural and recreational outlets. Penn's location is geographically ideal for an MBA/Biotechnology program. Philadelphia is one of the top four biotechnology hubs in the U.S. Over 70 biotechnology startups exist within a 50-mile radius of Penn's campus. The Philadelphia area is also home to many of the world’s largest pharmaceutical companies, such as GlaxoSmithKline, Merck, Wyeth and Bristol-Myers Squibb.